| Summary: | 碩士 === 中山醫學大學 === 生化暨生物科技研究所 === 102 === Human Parvovirus B19 (B19) infection is known to induce apoptosis and liver dysfunction. Cystamine is indicated in preventing apoptosis and it has been demonstrated to be beneficial on attenuating the hepatic injury in mice. Since our previous study demonstrated that B19-NS1 in development of autoimmunity by inducing apoptosis and aggravates liver injury, we herein intend to investigate the effect of cystamine on B19-NS1 induced hepatic iniury in BALB/c mice. For cystamine treatment, B19-NS1 BALB/c mice were injected intraperitoneally (i.p.) with cystamine daily for 14 days. Immunoblotting assay was performed to examine the signaling of inflammation in liver from B19-NS1 BALB/c mice given cystamine. Significant reduction of hepatic MMP-9 / MMP-2 activity ratio and decreased phosphorylation of p38, ERK, JNK, IKK-α, IκB and NF-κB (p-p65) proteins were observed in livers from B19-NS1 BALB/c mice given cystamine. Additionally, inflammation associated proteins, including MMP-9, CRP, IL-1β, IL-6 and TNF-α, were significantly decreased in the livers of B19-NS1 BALB/c mice given cystamine. Altogether, these results indicate that Cystamine has the protective effects against human parvovirus B19-NS1 induced hepatic injury.
|
|---|
